Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA®
from prior brimonidine 0.2%/timolol 0.5% fixed combination (COMBIGAN®) therapy in patients
with open-angle glaucoma or ocular hypertension and uncontrolled intraocular pressure (IOP).
Phase:
Phase 4
Details
Lead Sponsor:
Alcon Research
Treatments:
Brimonidine Tartrate, Timolol Maleate Drug Combination Brinzolamide Maleic acid Timolol